Novel CAR T ‘Promising’ for B-cell Lymphomas After Relapse from Previous Therapy

A next-generation “armored” CAR T cell therapy showed promising results in patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including commercially available CAR T cell therapies. “The fact that there are patients who continue to be in complete remission two-plus years later was very encouraging,” said Jakub Svoboda, MD, an associate professor of Hematology-Oncology, who published the clinical trial results in the New England Journal of Medicine, alongside Carl June, MD, the Richard W. Vague Professor in Immunotherapy, and Penn colleagues.